LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 187

Search options

  1. Article ; Online: Eureka Moment-Innovation Comes of an Age in Light Chain Amyloidosis.

    Sanchorawala, Vaishali

    JCO oncology practice

    2023  Volume 19, Issue 5, Page(s) 276–277

    MeSH term(s) Humans ; Amyloidosis/complications
    Language English
    Publishing date 2023-02-28
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 3028198-2
    ISSN 2688-1535 ; 2688-1527
    ISSN (online) 2688-1535
    ISSN 2688-1527
    DOI 10.1200/OP.23.00033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7198: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis.

    Sanchorawala, Vaishali

    HemaSphere

    2022  Volume 6, Issue 2, Page(s) e681

    Language English
    Publishing date 2022-01-27
    Publishing country United States
    Document type Editorial
    ISSN 2572-9241
    ISSN (online) 2572-9241
    DOI 10.1097/HS9.0000000000000681
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.

    Sanchorawala, Vaishali

    Acta haematologica

    2020  Volume 143, Issue 4, Page(s) 381–387

    Abstract: AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was ... ...

    Abstract AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in myeloma. This application has evolved significantly over the past three decades. This review provides a comprehensive assessment of eligibility criteria, stem cell collection, and mobilization strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies as well as long-term outcome with respect to survival, hematologic response and relapse as well as organ responses following stem cell transplantation. Continued efforts to refine patient selection and management, and incorporate novel anti-plasma cell agents in combination or sequentially to further improve outcomes in AL amyloidosis are also discussed.
    MeSH term(s) Combined Modality Therapy ; Disease Management ; Hematopoietic Stem Cell Mobilization ; Humans ; Immunoglobulin Light-chain Amyloidosis/diagnosis ; Immunoglobulin Light-chain Amyloidosis/etiology ; Immunoglobulin Light-chain Amyloidosis/therapy ; Melphalan/administration & dosage ; Myeloablative Agonists/administration & dosage ; Organ Specificity ; Peripheral Blood Stem Cell Transplantation/adverse effects ; Peripheral Blood Stem Cell Transplantation/methods ; Postoperative Care ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods ; Transplantation, Autologous ; Treatment Outcome
    Chemical Substances Myeloablative Agonists ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2020-04-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000506498
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

    Sanchorawala, Vaishali

    Blood advances

    2019  Volume 3, Issue 2, Page(s) 216–218

    MeSH term(s) Humans ; Immunoglobulin Light-chain Amyloidosis/diagnosis ; Immunoglobulin Light-chain Amyloidosis/therapy ; Quality of Life ; Recurrence ; Retreatment ; Stem Cell Transplantation ; Symptom Assessment ; Time-to-Treatment ; Treatment Outcome
    Language English
    Publishing date 2019-01-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2876449-3
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2018021261
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Systemic Amyloidosis and Kidney Transplantation: An Update.

    Anand, Shankara K / Sanchorawala, Vaishali / Verma, Ashish

    Seminars in nephrology

    2024  , Page(s) 151496

    Abstract: Amyloidosis is a heterogeneous disorder characterized by abnormal protein aggregate deposition that often leads to kidney involvement and end-stage kidney disease. With advancements in diagnostic techniques and treatment options, the prevalence of ... ...

    Abstract Amyloidosis is a heterogeneous disorder characterized by abnormal protein aggregate deposition that often leads to kidney involvement and end-stage kidney disease. With advancements in diagnostic techniques and treatment options, the prevalence of patients with amyloidosis requiring chronic dialysis has increased. Kidney transplantation is a promising avenue for extending survival and enhancing quality of life in these patients. However, the complex and heterogeneous nature of amyloidosis presents challenges in determining optimal referral timing for transplantation and managing post-transplantation course. This review focuses on recent developments and outcomes of kidney transplantation for amyloidosis-related end-stage kidney disease. This review also aims to guide clinical decision-making and improve management of patients with amyloidosis-associated kidney disease, offering insights into optimizing patient selection and post-transplant care for favorable outcomes.
    Language English
    Publishing date 2024-03-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604652-6
    ISSN 1558-4488 ; 0270-9295
    ISSN (online) 1558-4488
    ISSN 0270-9295
    DOI 10.1016/j.semnephrol.2024.151496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 784: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Daratumumab in AL amyloidosis.

    Wechalekar, Ashutosh D / Sanchorawala, Vaishali

    Blood

    2022  Volume 140, Issue 22, Page(s) 2317–2322

    Abstract: Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing, ...

    Abstract Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove amyloid deposits remain under study, but are, as yet, elusive. We review the progress of treatment in AL amyloidosis, the impact of daratumumab, and the next steps after treatment.
    MeSH term(s) Humans ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Amyloidosis/drug therapy
    Chemical Substances daratumumab (4Z63YK6E0E) ; Antibodies, Monoclonal
    Language English
    Publishing date 2022-05-02
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2021014613
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.

    Abdallah, Maya / Sanchorawala, Vaishali

    The American journal of medicine

    2022  Volume 135 Suppl 1, Page(s) S30–S37

    Abstract: The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data have shown promising results for several novel agents. We review the management of AL amyloidosis, including factors that determine transplant eligibility, treatment ... ...

    Abstract The management of immunoglobulin light chain (AL) amyloidosis is complex. Emerging data have shown promising results for several novel agents. We review the management of AL amyloidosis, including factors that determine transplant eligibility, treatment options for transplant-ineligible patients, and treatment options for relapsed/refractory AL amyloidosis. For carefully selected patients, high-dose melphalan and stem cell transplantation is recommended. Transplant eligibility criteria generally include biopsy-proven amyloidosis, evidence of a plasma cell dyscrasia, involvement of at least one major organ, and adequate performance status. For transplant-ineligible patients, bortezomib-based regimens are recommended, including: 1) bortezomib, oral melphalan, and dexamethasone (BMDex); 2) bortezomib, cyclophosphamide, and dexamethasone (CyBorD or VCd); and 3) subcutaneous daratumumab (DARA SC) and VCd. The latter option is based on a landmark trial that led to the first US Food and Drug Administration-approved therapy for AL amyloidosis. For relapsed/refractory disease, novel therapeutics including proteosome inhibitors, immunomodulatory agents, and monoclonal antibodies have shown promising results. In this review, we summarize data for various therapeutics in different clinical scenarios of AL amyloidosis.
    MeSH term(s) Amyloidosis ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunoglobulin Light-chain Amyloidosis/chemically induced ; Immunoglobulin Light-chain Amyloidosis/drug therapy ; Melphalan/therapeutic use ; Stem Cell Transplantation
    Chemical Substances Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2022-01-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80015-6
    ISSN 1555-7162 ; 1873-2178 ; 0002-9343 ; 1548-2766
    ISSN (online) 1555-7162 ; 1873-2178
    ISSN 0002-9343 ; 1548-2766
    DOI 10.1016/j.amjmed.2022.01.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.289: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Beyond Survival in AL amyloidosis

    Hamza Hassan / Vaishali Sanchorawala

    Hemato, Vol 3, Iss 4, Pp 38-

    Identifying and Satisfying Patients’ Needs

    2022  Volume 46

    Abstract: The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosis and treatment itself. Early diagnosis is critical in improving patient outcomes; however, given the nonspecific nature of the symptoms, most patients ... ...

    Abstract The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosis and treatment itself. Early diagnosis is critical in improving patient outcomes; however, given the nonspecific nature of the symptoms, most patients with AL amyloidosis require evaluation by multiple specialists, resulting in significant delays in diagnosis of up to 3 years. An early and accurate diagnosis can help reduce the psychological toll of the patient’s journey to diagnosis. Given the high symptom burden and complex process of diagnosis, it is not surprising that patients with AL amyloidosis report worse health-related quality of life than the general population. Organ dysfunction associated with AL amyloidosis also may make the treatment directed towards plasma cell clone difficult to tolerate, leading to morbidity and mortality. Furthermore, supportive care requires an integrated, multidimensional and patient-centered approach to improve survival and feelings of well-being, as organ responses lag behind hematologic responses. The impact of AL amyloidosis is often devastating for the patient and may last beyond the effects of treatment. Future research is needed to study and assess the needs of survivors of AL amyloidosis utilizing valid, reliable and standardized measures.
    Keywords light-chain amyloidosis ; survivorship ; supportive care ; QOL ; Medicine ; R
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.

    Staron, Andrew / Zheng, Luke / Doros, Gheorghe / Sanchorawala, Vaishali

    Blood cancer journal

    2022  Volume 12, Issue 7, Page(s) 100

    MeSH term(s) African Americans/genetics ; Cytogenetic Analysis ; Cytogenetics ; Humans ; Immunoglobulin Light-chain Amyloidosis ; Whites/genetics
    Language English
    Publishing date 2022-07-04
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-022-00697-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients' narratives on medical students' knowledge, attitudes, and behavioral intent.

    Adebayo, Adebanke L / Rowan, Katherine E / Sanchorawala, Vaishali / Boedicker, Mackenzie N / Boedicker, Deborah D

    MedEdPublish (2016)

    2023  Volume 13, Page(s) 32

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2023-06-28
    Publishing country Scotland
    Document type Journal Article
    ISSN 2312-7996
    ISSN (online) 2312-7996
    DOI 10.12688/mep.19631.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top